Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Total Valuation
BioCryst has a market cap or net worth of $1.49B. The enterprise value is $2.14B.
Market Cap$1.49B
Enterprise Value$2.14B
Share Statistics
BioCryst has 210,543,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding210,543,230
Owned by Insiders1.77%
Owned by Institutions1.71%
Financial Efficiency
BioCryst’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is -0.71%.
Return on Equity (ROE)0.19
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-0.71%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee777.09K
Profits Per Employee-153.24K
Employee Count580
Asset Turnover0.92
Inventory Turnover1.52
Valuation Ratios
The current PE Ratio of BioCryst is ―. BioCryst’s PEG ratio is 0.28.
PE Ratio―
PS Ratio3.45
PB Ratio-3.27
Price to Fair Value-3.27
Price to FCF-29.25
Price to Operating Cash Flow-285.85
PEG Ratio0.28
Income Statement
In the last 12 months, BioCryst had revenue of 450.71M and earned -88.88M in profits. Earnings per share was -0.43.
Revenue450.71M
Gross Profit438.23M
Operating Income-2.54M
Pretax Income-86.95M
Net Income-88.88M
EBITDA12.81M
Earnings Per Share (EPS)-0.43
Cash Flow
In the last 12 months, operating cash flow was 49.68M and capital expenditures -2.34M, giving a free cash flow of 47.34M billion.
Operating Cash Flow49.68M
Free Cash Flow47.34M
Free Cash Flow per Share0.22
Dividends & Yields
BioCryst pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change-13.43%
50-Day Moving Average7.45
200-Day Moving Average8.43
Relative Strength Index (RSI)47.66
Average Volume (3m)6.54M
Important Dates
BioCryst upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateNov 3, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
BioCryst as a current ratio of 2.63, with Debt / Equity ratio of -175.27%
Current Ratio2.63
Quick Ratio2.58
Debt to Market Cap0.53
Net Debt to EBITDA57.52
Interest Coverage Ratio-0.03
Taxes
In the past 12 months, BioCryst has paid 1.93M in taxes.
Income Tax1.93M
Effective Tax Rate-0.02
Enterprise Valuation
BioCryst EV to EBITDA ratio is 178.88, with an EV/FCF ratio of -43.11.
EV to Sales5.08
EV to EBITDA178.88
EV to Free Cash Flow-43.11
EV to Operating Cash Flow-44.04
Balance Sheet
BioCryst has $212.87M in cash and marketable securities with $683.11M in debt, giving a net cash position of -$470.24M billion.
Cash & Marketable Securities$212.87M
Total Debt$683.11M
Net Cash-$470.24M
Net Cash Per Share-$2.23
Tangible Book Value Per Share-$2.30
Margins
Gross margin is 97.39%, with operating margin of -0.56%, and net profit margin of -19.72%.
Gross Margin97.39%
Operating Margin-0.56%
Pretax Margin-19.29%
Net Profit Margin-19.72%
EBITDA Margin2.84%
EBIT Margin2.57%
Analyst Forecast
The average price target for BioCryst is $19.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.27
Price Target Upside171.79% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast45.38%
EPS Growth Forecast92.85%